SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences - Quaterly Results

10 Feb 2026 Evaluate
The sales declined to Rs. 22836.00 millions for the December 2025 quarter as compared to Rs. 25159.00 millions during the corresponding quarter last year.The Net Profit of the company slipped to Rs. 2965.00 millions from Rs. 4706.00 millions, a decline of -37.00% on QoQ basis.Operating Profit reported a sharp decline to 6728.00 millions from 7260.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 22836.00 25159.00 -9.23 77431.00 92967.00 -16.71 151163.00 108187.00 39.72
Other Income 4738.00 775.00 511.35 15682.00 5654.00 177.36 9058.00 11595.00 -21.88
PBIDT 6728.00 7260.00 -7.33 31087.00 44744.00 -30.52 84325.00 51435.00 63.94
Interest 1160.00 972.00 19.34 3674.00 3085.00 19.09 4639.00 3907.00 18.74
PBDT 4967.00 6288.00 -21.01 26812.00 41659.00 -35.64 79686.00 47442.00 67.97
Depreciation 1443.00 1316.00 9.65 4103.00 3959.00 3.64 5239.00 5044.00 3.87
PBT 3524.00 4972.00 -29.12 22709.00 37700.00 -39.76 74447.00 42398.00 75.59
TAX 559.00 266.00 110.15 4331.00 8088.00 -46.45 16698.00 7983.00 109.17
Deferred Tax -259.00 508.00 -150.98 -200.00 528.00 -137.88 873.00 -1360.00 -164.19
PAT 2965.00 4706.00 -37.00 18378.00 29612.00 -37.94 57749.00 34415.00 67.80
Equity 1006.00 1006.00 0.00 1006.00 1006.00 0.00 1006.00 1006.00 0.00
PBIDTM(%) 29.46 28.86 2.10 40.15 48.13 -16.58 55.78 47.54 17.33

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×